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program NP coordinates care with the patient’s clinic physician
and Physician Assistant (PA). An extensive assessment is performed
around the time the patient will be leaving the transplant center.
Baseline data and outcome tracking will include incidence and
severity of chronic graft vs host disease, infections, endocrine and
nutritional disorders, quality of life, and survival. Information
about assessment tools and outcomes will be shared, as well as a
case study.
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IMPROVING CLINICAL OUTCOMES UTILIZING A BMT UNIT-BASED
CLINICAL PRACTICE COUNCIL
Adlard, K., Patterson, M. Children’s Hospital of Orange County, Or-
ange, CA.
A BMT unit-based Clinical Practice Council (CPC) was formed
in our Oncology Intensive Care Unit (OICU) to address clinical
issues and improve clinical outcomes for our pediatric BMT pa-
tients. The nurses in the OICU were concerned about several
patient care issues and inconsistent clinical practice. Due to the
nursing shortage, our unit is often staffed with new graduate
nurses, registry and traveling nurses, and nurses ﬂoating from
other units, which often results in inconsistent clinical practice. In
order to address the clinical issues and increase staff involvement,
the Clinical Director and Clinical Nurse Specialist (CNS) devel-
oped a unit-based Clinical Practice Council. The Clinical Practice
Council consists of the Charge Nurses, staff nurses from both
shifts, the BMT Coordinators, the Clinical Director, and the CNS.
At our ﬁrst meeting, the nurses were asked to brainstorm about the
clinical issues that they were concerned about and then prioritize
the issues. All Clinical Practice Council members were asked to
“volunteer” for one or more clinical issues that they would like to
research and determine best practices. The staff embraced the
challenge and went straight to work. The nurses have worked on a
variety of issues that have resulted in practice changes and im-
proved clinical outcomes. For example, we have made improve-
ments in our BMT diet, calorie counts, blood specimen collection
from central venous catheters, documentation of ﬂuid balance,
discharge education, and blood product utilization. Recommenda-
tions for clinical practice changes are presented to the BMT Med-
ical Director, Oncologists, and other disciplines as needed for
review and approval. The Clinical Practice Council has been suc-
cessful in improving clinical outcomes, increasing staff involve-
ment and job satisfaction, and increasing patient and family satis-
faction. Based on the success of this practice council model in the
OICU, we have implemented Clinical Practice Councils in our
Cancer Institute Clinic and Hematology/Oncology Unit.
486
ARSENIC TRIOXIDE IN COMBINATION WITH ASCORBIC ACID AND
HIGH-DOSE MELPHALAN IS SAFE FOR PATIENT WITH MM UNDERGO-
ING AN AUTOLOGOUS TRANSPLANT
Libunao, F.R., Roden, L.X., Davis, M.S., Champlin, R., Giralt, S.,
Qazilbash, M. The University of Texas M. D. Anderson Cancer Center,
Houston, TX.
Purpose: To evaluate the safety of a new conditioning regimen
of arsenic trioxide (ATO), ascorbic acid (AA), and Melphalan for
patient with multiple myeloma undergoing an autologous hema-
topoietic stem cell transplantation. Rationale: ATO is an active
agent against multiple myeloma and has been shown to have
synergistic effect with melphalan and ascorbic acid AA both in vitro
and in vivo.Design: Phase I/II clinical trialMethods: Twenty-ﬁve
patients with multiple myeloma (11 females, 14 males median age:
53, range: 49-69) were treated between 4/04 and 1/05. All patient
received melphalan 100 mg/m2 IV on days 4 and 3 and AA
1000 mg/day IV on days 9 to 3. Patients were randomized to 3
arms; no ATO (arm 1), ATO 0.15 mg/kg IV on days 9 to 3
(arm 2) and ATO 0.25 mg/kg IV on days 9 to 3 (arm 3). Seven
patients had a prior autograft. Median CD34 cells dose infused was
4.4  106/kg (range 2.3-10.9). Results: With a median F/U of 7.1
months post autograft, no dose-limiting toxicity or non-relapse
mortality was seen. Median ATO level on day 0 in arms 1, 2, and
3 were 0.2, 26.3 and 46.2 ng/ml, respectively. Median time to
neutrophil engraftment (ANC 	500/ dl) was 9 days. There were
no engraftment failures or delays in the ATO arms. Toxicity was
limited grade I or II nausea, vomiting and diarrhea. See Table 1.
Conclusions: Arsenic trioxide given in combination with melpha-
lan and ascorbic acid as preparative regimen for an autograft is safe
and well tolerated. No dose limiting toxicity or adverse effects or
delays in engraftment were seen. No difference in infections was
noted at any dose level (Table1).
Table 1. Toxicities
Patient
no. Dose Level Toxicities Day 0 Toxicities Day 15
Toxicities
Day 30
1 placebo none none none
2 .15mg/kg/day N&V gr 1 none none
3 placebo N & V gr 1 N & V gr 1, dia
gr 1, muco gr 2
none
4 .25mg/kg/day none N & V gr 1 none
5 .15mg/kg/day N & V gr 1, mucogr
1, diarr gr 1,
perip edema gr 1
none none
6 .15mg/kg/day N & V gr 1, diarr gr
1
none none
7 .15mg/kg/day N & V gr 1, diarr gr
1, fever gr 1
none none
8 .15mg/kg/day N & V gr 1, fever gr
1
diarr gr 1 none
9 .15mg/kg/day diarr gr 1, mucos gr
1, pedal edema gr
1, N & V gr 1
none none
10 .15mg/kg/day hypert gr 1, neu fev
gr 1
N & V gr 1, ALT,
AST gr 1,
creatgr 1, GI &
chest pain gr 1
none
11 .15mg/kg/day none none none
12 .15mg/kg/day N & V gr 1, diarr gr
1, mucos gr 1
none N & V gr 1
13 .15mg/kg/day N & V gr 1 none none
14 .15mg/kg/day perip edema gr 1,
diarr gr 1
N & V gr 1 none
15 .15mg/kg/day nausea gr 1 perip edema gr 1 none
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ADVERSE EVENTS TO CAMPATH IN A PEDIATRIC SETTING
Klinger, E.F., Daum, C.D., Neudorf, S.M.L., Snyder, R., Simpson, L.M.
Children’s Hospital of Orange County (CHOC), Orange, CA.
Alemtuzumab (Campath) has been used to prevent graft versus
host disease in adult recipients of unrelated donor bone marrow.
Given the limited experience using Campath in pediatrics, we are
reporting the incidence of adverse reactions.
Campath (0.2 mg/kg/day IV  5 days) was given to recipients on
day 8 or 9 prior to receiving grafts from a HLA matched unrelated
donor. All patients received Acetaminophen (10-15 mg/kg/dose
PO, 650 mg max) and Diphenhydramine (1mg/kg/dose PO/IV) to
prevent adverse reactions. Adverse events were identiﬁed from the
retrospective review of nursing and physician progress notes. Re-
sults: 10 patients received Campath. All 10 patients had reactions
to Campath including fever (n  7), chills (n  3), hypotension
(n 2), urticaria (n 1), anxiety (n 1), headache (n 1), nausea
and emesis (n  1). Four patients received IVIG during their
preparative therapy. Given the high incidence of adverse reactions
despite premedication, the program adapted the following practice
changes: (1) BMT order sets were revised to encompass immediate
intervention algorithm for wider range of adverse reactions. The
algorithm calls for a stop of infusion, drug intervention(s), and
physician notiﬁcation. If SOB develops, Hydrocortisone (1-2 mg/
kg/dose IV, 100 mg max) will be given, NS bolus (10-20 mg/kg/
dose, 1000 ml max) will be added for hypotension, Meperidine (1
mg/kg/dose IV, 50mg max) for rigors and Ranitidine (1-2 mg/kg/
dose IV, 50 mg max) for rash. (2) Campath administration is
scheduled in the day shift in order to facilitate close monitoring
and medical staff availability. (3) IVIG will be given either prior to
start of conditioning or at day 1. (4) The program will collect
prospect data to evaluate the efﬁcacy of the practice change.
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